Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
TIC10
As low as
CHF 155.00
In stock
Only %1 left
CDX-T0898-M100100 mgCHF 155.00
Specifications / Handling
| Product Details | |
|---|---|
| Synonyms | ONC201; Dordaviprone; 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
| Product Type | Chemical |
| Properties | |
| Formula | C24H26N4O |
| MW | 386.5 |
| CAS | 1616632-77-9 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Yellow solid. |
| Solubility | Soluble in DMF (20mg/ml), ethanol (10mg/ml) or DMSO (10mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | VLULRUCCHYVXOH-UHFFFAOYSA-N |
| Smiles | CC1=CC=CC=C1CN(C2=O)C3=NCCN3C4=C2CN(CC5=CC=CC=C5)CC4 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Scientific Background Information
Product Description
TIC10 (ONC201; Dordaviprone), is a first-in-class imipridone anticancer compound widely used in oncology and cancer biology research. It is orally active, stable, and crosses the blood-brain barrier. TIC10 induces tumor cell apoptosis. As a selective antagonist of the dopamine receptor D2 (DRD2) and an agonist of the mitochondrial protease ClpP, leading to disruption of pro-survival signaling and induction of tumor-selective apoptosis. TIC10 is recognized for its ability to activate the TRAIL (TNF-related apoptosis-inducing ligand) pathway while concurrently inhibiting Akt signaling, a central regulator of cancer cell survival and resistance.
Product-specific References
[1] J.E. Allen, et al.; Sci. Transl. Med. 5, 171ra117 (2013) | [2] J.E. Allen, et al.; Cancer Res. 75, 1668 (2015) | [3] J. Ishizawa, et al.; Sci. Signal. 9, ra17 (2016) | [4] J.E. Allen, et al.; Oncotarget 7, 74380 (2016) (Review) | [5] V.V. Prabhu, et al.; Neoplasia 22, 725 (2020) (Review) | [6] E.R. Bonner, et al.; Neuro-oncology 23, 542 (2021) | [7] B. Shenoy, et al.; Curr
You're in the Switzerland store. Not in Switzerland? Choose your country
You're in the Switzerland store (prices in CHF, shipping to Switzerland only). Ordering from another country? Please select it below.
Please note that not all products are available in every country store. Choose your country before starting the ordering process.
Country
Switzerland
United Kingdom
France
Germany
Austria
Italy
South Korea
United States
Argentina
Australia
Belgium
Bosnia and Herzegovina
Brazil
Canada
Chile
China
Colombia
Cyprus
Czech Republic
Denmark
Ecuador
Egypt
Estonia
Finland
Greece
Hong Kong
Hungary
India
Iran
Iraq
Ireland
Israel
Japan
Latvia
Lithuania
Luxembourg
Malaysia
Mexico
Netherlands
New Zealand
Norway
Pakistan
Peru
Poland
Portugal
Romania
Russia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Syria
Taiwan
Thailand
Turkey
Uruguay
Venezuela
Other Country
No country found




Download PDF